Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Aceclidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.96 |
| ▸ | CHRNA7 known ✓ | P36544 | 4/20 | 0.50 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.50 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.49 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aceclidine SCHEMBL121393 | 0.98 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| (S)-Aceclidine SCHEMBL9146471 | 0.98 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| (R)-Aceclidine SCHEMBL9146752 | 0.98 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL10574679 | 0.89 | CHRM2 (0.82) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL16933508 | 0.84 | CHRM2 (0.75) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Oxalic Acid SCHEMBL10571388 | 0.84 | CHRM2 (0.74) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3743481 | 0.82 | CHRM2 (0.71) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Aceclidine SCHEMBL4140116 | 0.82 | CHRM2 (0.69) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL10447494 | 0.81 | CHRM2 (0.66) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL3314029 | 0.81 | CHRM2 (0.65) | CHRM2CHRM1MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091207-A1 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | LENZ THERAPEUTICS OPERATIONS, INC. | 2024-03-21 | — | — | US | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| US-11648247-B1 | Compositions and methods for the treatment of presbyopia | LENZ THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | claimed |
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-19 | — | — | US | claimed |
| US-20220233434-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2022-07-28 | — | — | US | claimed |
| EP-4025302-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-13 | — | — | EP | claimed |
| CN-114340733-A | Regeneration of connective tissue function and phenotype by Npas2 inhibition | 加利福尼亚大学董事会 | 2022-04-12 | — | — | CN | claimed |
| US-11273150-B2 | Compositions and methods for the treatment of presbyopia | LENZ THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | claimed |
| CN-113164452-A | Methods and compositions for treating presbyopia, mydriasis and other ocular disorders | 奥库菲尔制药股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-10959990-B2 | Compositions and methods for the treatment of presbyopia | PRESBYOPIA THERAPIES, INC (US) | 2021-03-30 | — | — | US | claimed |
| WO-2021046438-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-11 | — | — | WO | claimed |
| US-20210038574-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2021-02-11 | — | — | US | claimed |
| US-20200281906-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2020-09-10 | — | — | US | claimed |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-121955261-A | Analysis method of aceclidine hydrochloride in biological matrix | 苏州华测生物技术有限公司 | 2026-05-01 | — | — | CN | disclosed |
| US-20050287565-A1 | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | GALAPAGOS N.V. (BE) | 2005-12-29 | — | — | US | disclosed |
| EP-1534239-A2 | PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE | BAXTER INTERNATIONAL INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004054500-A2 | PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE | BAXTER INTERNATIONAL INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030096013-A1 | Preparation of submicron sized particles with polymorph control | BAXTER INTERNATIONAL INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | PER2, NCBP2, NOTCH1 | CHRM2 3343/4885CHRM1 4442/4885CHRNA7 2401/4885 |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | CHRM5, CHRM3, CHRM2 | CHRM2 3/4885CHRM1 5/4885CHRNA7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.